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Aim: In the present study, the effect of chemo and radio therapies on serum trace elements content and antioxidant activity in blood 
serum of cervical cancer patients was evaluated. Methods: Among 104 cervical cancer patients selected for the present study, 54 and 
50 patients were treated with chemo- and radiotherapy respectively. Plasma Se, Zn, Cu and some enzymatic antioxidants activities 
were estimated in serum before and after the treatment. Results: The decreased levels of serum trace elements, glutathione peroxidase 
activity and total antioxidant capacity, and increased malondialdehyde, glutathion reductase was observed in cervical cancer patients 
when compared to healthy controls. The increased concentration of serum Se, Zn was observed in patients treated with chemothera-
py. Simultaneously there was a significant (P < 0.001) increase in glutathione peroxidase and total antioxidant capacity, and signifi-
cant decrease (P < 0.05) in malondialdehyde and glutathion reductase levels in the serum of patients treated with chemotherapy 
compared to the patients treated with radiotherapy. Conclusion: The results demonstrated that chemotherapy but not radiotherapy 
results in significant increase in the trace elements levels and antioxidant activities in blood serum of cervical cancer patients.
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Cervical cancer is one of the most prevalent can-
cers world-wide and the most recent compilation 
of data indicates that an estimated 4������� new 
cervical cancer cases occ�r ann�ally among women 
world-wide. H�man papilloma vir�s is the main ca�s-
ative agent for the cervical cancer along with some 
other risk factors. It is acknowledged that reactive spe-
cies �ROS� play an important role in many pathological 
conditions incl�ding cancer. Under normal conditions 
their harmf�l effects �pon the cells are ne�tralized 
to a large extent by a cascade of antioxidant defense 
mechanisms of the body. When overwhelming genera-
tion of ROS malf�nction of antioxidant balance occ�rs 
in the body� the system is considered to be in a state 
of oxidative stress [�]. It has been stated that genera-
tion of ROS d�ring cancer development interferes with 
organ f�nctions directly by damaging proteins� fats 
and n�cleotides [�].
Antioxidant s�pplementation d�ring radiation 
therapy possesses a con�ndr�m for the radiation on-
cologist� as antioxidants that defend normal cells from 
reactive oxygen species may provide the same ben-
efits to cancer cells and red�ce the efficacy of treat-
ment. Short- and long-term inj�ry to normal healthy 
cells� incl�ding tiss�e damage and risk of oncogenic 
transformation [�]� can be prevented by antioxidants. 
New findings that antioxidants ind�ce apoptosis in t�-
mor cells and protect patients from severe side effects 
of radiation treatment may prove these compo�nds 
�sef�l in f�t�re adj�vant therapy.
At optimal doses� the radiation �sed in therapy 
depletes cell�lar alphatocopherol in normal cells� 
thereby increasing their risk of damage; animal st�d-
ies show that whole-body expos�re to X-ray irradiation 
decreases the concentrations of vitamins C and E in tis-
s�es [4]. A decline in tiss�e vitamin E and Se d�ring 
radiation therapy for breast cancer and a fall in vitamins 
A� C� E� and Se d�ring breast cancer treatment with 
ROS-prod�cing adriamycine may increase normal 
tiss�e sensitivity to radiation damage.
Seleni�m is one of the key components of anti-
oxidative mechanism which belongs to every cell� and 
there is evidence that this essential trace element have 
anticancer properties. The large body of evidence 
s�ggested the protective role of seleni�m �Se� in dif-
ferent cancers incl�ding cervical cancer. Se exerts 
its chemopreventive effect in different ways� s�ch 
as a defense against oxidative damage by scaveng-
ing the ROS and improves the synthesis of enzymatic 
antioxidant gl�tathione peroxidase �GPx� [�� 6]. The 
cytosolic GPx is the best selenoprotein� characterized 
in mammalian cells� capable of red�cing eq�ivalents 
from gl�tathione to detoxify hydrogen and lipid per-
oxidation [�]. In relation to the fortification with Se� 
it has been demonstrated that Se and vitamin E �toco-
pherol� are interrelated in the in vivo antioxidant system 
by a do�ble way� first� the formation of GPx contrib�tes 
to the decomposition of lipid hydroperoxides into 
non-pro-oxidant species; second� tocopherol acts 
as a chain-breaking antioxidant [8� �].
Therefore� the present st�dy eval�ated the effect 
of chemo and radiotherapy on ser�m trace element 
levels and antioxidant capacity in cervical cancer 
patients.
MATERIALS AND METHODS
Sample collection. Ser�m samples of cervical 
cancer patients were collected from the Govern-
ment Maternity Hospital� Tir�pati� and Department 
of Radiation Oncology� Government General Hos-
pital� G�nt�r� Andhra Pradesh. The pop�lation in-
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cl�ded ��4 ��4+��� cervical cancer patients� aged 
�� to �� years �46.��±4 years�� randomly collected 
from the hospitals. Ser�m samples from age matched 
�� healthy donors ������ years� were collected 
as control samples. The incl�sion criteria for the se-
lection of cervical cancer patients were proven by the 
biopsy/histopathology� these patients had any other 
pathologies and were treated only with chemotherapy 
or radiotherapy.
For histopathological analysis� t�mors were classi-
fied according to TNM classification system [��]. From 
��4 cervical cancer patients� �4 patients were treated 
with chemotherapy �cisplatin + mitomycin� and �� pa-
tients were treated with radiotherapy �Cent Gy/sec�.
Ethical approval. The experimental protocol and 
ethical aspects were approved by the Instit�tional 
Ethical Committee �IEC�� Sri Venkateswara Medical 
College� Tir�pati along with the patient consent forms.
Biochemical studies. Approximately � ml of blood 
was collected before and after treatment �chemo- 
or radiotherapy�. Ser�m was separated from the blood 
and stored at -4� °C �ntil analysis.
Atomic adsorption spectroscopy was �sed to ana-
lyze the concentration of ser�m trace elements like Se 
[��]� zinc and copper [��]. The GPx activity [��] and 
total antioxidant ability [�4] was meas�red by spectro-
photometric method. Ser�m malondialdehyde �MDA� 
was determined by the method [��] and gl�tathione 
red�ctase �GR� activity was meas�red in the ser�m 
by the method described in [�6].
Statistical analysis. The data were analysed �s-
ing a statistical package for social sciences �SPSS 
��.� version�. A one way ANOVA was performed 
followed by T�key’s test for comparison of res�lts 
between control and experimental gro�ps. All val�es 
were expressed as mean±S.E.
RESULTS
In this st�dy� ��4 cervical cancer patients were 
selected for therapy based on their t�mor stage and 
clinicopathological indexes �Table ��. All these pa-
tients had decreased levels of trace elements� GPx 
and total antioxidant activity compared to the healthy 
controls �Table ��. Increased concentration of ser�m 
trace elements was observed in patients treated with 
chemotherapy �P < �.��� vers�s patients treated 
with radiotherapy. Interestingly� there was significant 
�P < �.���� increase in the activity of total antioxidant 
activity ��.��±�.��� and GPx ��8.�±�.8�� in patients 
treated with chemotherapy� and there is no significant 
change in these indexes ��.��±�.�4 and 4�.�±�.��� 
in radiotherapy treated patients.
The lipid peroxidation prod�ct� i.e. MDA levels� and 
GR were fo�nd to be increased ���.��±�.6� µl/l and 
�8.��±4.6� U/l� significantly in the ser�m of the pa-
tients with cervical cancer compared to the controls 
���.86±�.8� µl/l and 48.6�±�.�� U/l�� b�t there is no sig-
nificant changes in these indexes after the co�rses 
of chemotherapy or radiotherapy. However� after che-
motherapy� the decreased MDA and GR levels were 
registered compared to radiotherapy-treated gro�p.
Table 1. Characteristics of cervical cancer patients
№ Character Patients, n
1 Median age (range), years 104 (30–75)
2 Stage of cervical cancer
IIA 16
IIB 28
IIIA 34
IIIB 18
IV 8
3 Histological features
SCC 64
DSCC 12
M.D/WDSCC 6/15
Du SCC 4
In. SCC 3
4 Lymphnode involvement 26
No involvement of lymphnode 78
5 Treatment
Chemotherapy (cisplatin + mitomycin) 54
Radiotherapy
(80 centi Gy/30 sec — min. per cycle)
50
Notes: SCC — squamous cell carcinoma; DSCC — differentiated squamous 
cell carcinoma; M.D/WD SCC — moderately and well differentiated squamous 
cell carcinoma; Du SCC — ductal squamous cell carcinoma; In. SCC — inter-
mediate squamous cell carcinoma.
Table 2. Serum levels of trace elements and antioxidant status of cervical 
cancer patients before and after treatment
No Parameter Healthy con-trols (n = 50)
Before 
treatment 
(n = 104)
After treatment
Chemothera-
py (n = 54)
Radiothera-
py (n = 50)
1 Se (µg/dl) 13.83 ± 0.21 7.32 ± 0.59* 11.16 ± 0.32* 8.90 ± 1.23*
2 Zn (µg/dl) 89.45 ± 0.32 56.32 ± 0.43* 83.62 ± 4.76* 59.98 ± 2.76*
3 Cu (µg/dl) 98.76 ± 2.43 72.15 ± 2.8* 73.13±2.6*** 72.54±2.6***
4 Mn (µg/dl) 0.54 ± 0.12 0.23 ± 0.18* 0.49 ± 1.2* 0.32 ± 0.23*
5 GPx (nmol/
NADPH/min/
mg protein)
62.5 ± 3.82 42.4 ± 4.63* 58.2 ± 7.82* 43.2 ± 2.32**
6 MDA (µl/l) 8.89 ± 1.52 15.99 ± 2.63* 11.86±1.89 ** 14.78±0.54**
7 GR (U/l) 24.63 ± 0.46 58.59 ± 4.62 * 48.63±2.32** 54.41±1.56**
8 TAC (mmol/l) 3.34 ± 0.23 1.02 ± 0.46* 2.89 ± 0.12* 1.23 ± 0.34**
Notes: Values are mean ± SE. Values with different superscripts differ signi-
ficantly from values within the same row, by ANOVA and Tukey’s tests. *Sig-
nificant at P < 0.001; **significant at P < 0.05 and ***unsignificant; GPx — 
glutathione peroxidase; TAC — total antioxidant capacity; MDA — malondial-
dehyde, GR — glutathione reductase.
Correlation between Se and GPx. Ser�m sele-
ni�m was correlated with GPx at different levels� corre-
lation val�es is �.�� in healthy samples vers�s �.�� and 
�.6� in chemo- or radiotherapy treated patients 
respectively �Fig. � and ��. This correlation indicated 
that increased concentration of ser�m Se increases 
the antioxidant enzyme GPx� which is a seleni�m de-
pendent antioxidant.
38
39
40
41
42
43
44
4 5 6 7 8 9
Selenium
G
Px
Fig. 1. Correlation c�rve between Se and GPx after the che-
motherapy
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Fig. 2. Correlation c�rve between Se and GPx after the radio-
therapy
DISCUSSION
Chemotherapy involves administration of cyto-
toxic dr�gs that prevents growth and proliferation 
of neoplastic cell. Se is an antioxidant agent: it can 
can red�ce hydrogen peroxides� lipid and phospho-
lipids hydroperoxides via GPx� thereby dampening the 
propagation of free radicals and ROS.
In the present st�dy� decreased ser�m trace ele-
ments� especially Se levels were observed in cervical 
cancer patients as compared to healthy controls 
�Table ��. This is in accordance with observations that 
the patients with Crohns disease and cancer [��� �8] 
have significantly lowered ser�m Se than the controls. 
The epidemiological data s�ggest that cancer morta-
lity is inversely correlated with Se cons�mption and that 
people living in geographic areas with low Se content 
have higher rate of malignancies� especially gastroin-
testinal and breast cancer [��].
There is no significant effect of radiotherapy 
on antioxidant and trace elements in cervical cancer 
patients. A recent st�dy has demonstrated that there 
is no considerable change in ser�m antioxidant levels 
after radiotherapy in cervical cancer patients [��]. O�r 
res�lts were similar: no significant change in ser�m 
antioxidant levels especially GPx and total antioxidant 
activity after radiotherapy were fo�nd. However� after 
the chemotherapy� 8�% of the patients have shown in-
creased concentration of Se� Zn and Mn accompanied 
by GPx and total antioxidant activities. The similar find-
ings were reported in the st�dy [��] which indicated 
that GPx activity was significantly increased in breast 
cancer patients after chemotherapy. Fig. � and � show 
that there is correlation between ser�m Se and GPx 
in chemo and radiotherapy treated patients. The in-
creased Se concentration may be attrib�ted to the 
exogeno�s s�pplementation of dr�gs. Increased 
Se in ser�m of cancer patients ind�ces the increased 
prod�ction of Se dependent antioxidant mechanism 
like GPx� hence in the present st�dy GPx and total anti-
oxidant activity was increased in chemotherapy treated 
patients compared to radiotherapy treated patients.
It is well established that antioxidant defense 
system scavenges the free radicals directly or inter-
feres with the generation of free radical mediated 
events inhibiting the neoplastic process [��]. In the 
present st�dy� the ser�m antioxidant enzyme� i.e. 
MDA and GR activity was fo�nd to be increased 
significantly in patients with cervical cancer. Similar 
reports of raised antioxidant enzyme activities have 
been reported in patients with prostate cancer [��]. 
Gl�tathione red�ctase� an oxidative stress ind�cible 
enzyme� plays a considerable role in the peroxyl sca-
venging mechanism and in maintaining the f�nctional 
integration of the cell membranes. The rise in the acti-
vity of GR co�ld be d�e to its ind�ction to co�nter the 
effect of increased oxidative stress.
In the present st�dy� a significant elevation of se-
r�m MDA in cervical cancer patients in comparison 
to healthy controls has been observed. The reason for 
increased lipid peroxidation co�ld be d�e to increased 
generation of reactive oxygen species or s�ppres-
sion of the antioxidants defence mechanism in the 
metabolically active tiss�es. Recently it was reported 
the antioxidant defence was s�ppressed in vario�s 
colorectal cancer t�mors [�4].
Seleni�m is an essential trace element for animals 
incl�ding h�mans� has been shown to affect the f�nc-
tion of selenoproteins by being a part of active site 
in antioxidant enzymes like gl�tathione peroxidase 
and thioredoxin red�ctase. F�rthermore Se can acts 
as anticancer agent thro�gh the pla�sible mechanisms 
like stim�lation of imm�ne system and inhibition of cell 
proliferation [��]. The s�stainable pers�asive evidence 
indicates that Se can certainly play an important role 
in cancer prevention [�6].
M�ltiple lines of experimental evidence indicated 
that optimal s�pplementation with Se red�ces p�lmo-
nary metastasis of melanoma in mice [��]. Res�lts 
obtained with the gene therapy approach clearly 
demonstrated that CH�SeH can inhibit t�mor growth 
and prolong host s�rvival rate [�8]. The prevention 
of t�mor cell adhesion and migration is related to inhi-
bition of t�mor cell invasion into basement membrane 
[��]. It was also doc�mented that brief pre-expos�re 
of HeLa cells to micromolar concentration of selenite 
res�lted in a dose dependent decrease in the rate 
of their s�bseq�ent attachment to a solid matrix [��]. 
F�rther� the present findings also reveal a remarkable 
relationship between levels of trace elements vers�s 
antioxidants enzymatic system� especially Se vers�s 
GPx and the concentration of Se is directly proportional 
to the GPx activity. Consistent with the above findings 
it is important to maintain a constant balance in ser�m 
trace elements like Se in cancer patients which ind�ces 
the enhancement of antioxidant enzymes.
In concl�sion� we have registered the decreased 
concentration of trace elements� Se� GPx activity and 
increased activity of lipid peroxidation� GR in cervical 
cancer patients. However these indexes were sig-
nificantly improved after chemotherapy b�t not radio-
therapy. Hence� chemotherapy promotes an increase 
of the antioxidant defense.
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